|
| 37355358 | European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study. | Eur Urol | 2024 |
| 38087732 | Re: Which Patients with Metastatic Hormone-sensitive Prostate Cancer Benefit from Docetaxel: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Trials. | Eur Urol | 2024 |
| 37951819 | Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.07.010. | Eur Urol Oncol | 2024 |
| 37838554 | Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. Eur Urol Oncol. 2023;6:590-596. | Eur Urol Oncol | 2024 |
| 37833180 | Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol 2022;83:521-33. | Eur Urol | 2024 |
| 38044179 | Atlas of Intracorporeal Orthotopic Neobladder Techniques After Robot-assisted Radical Cystectomy and Systematic Review of Clinical Outcomes. | Eur Urol | 2024 |
| 37604763 | Real-world Outcomes and Predictive Biomarkers for <sup>177</sup>Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study. | Eur Urol Oncol | 2024 |
| 37055663 | Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy. | Prostate Cancer Prostatic Dis | 2024 |
| 37455217 | Re: Ragheed Saoud, Varat Woranisarakul, Gladell P. Paner, et al. Physician Perception of Grade Group 1 Prostate Cancer. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.04.002. | Eur Urol Focus | 2024 |
| 37414703 | Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data. | Eur Urol | 2024 |
| 36216967 | Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis. | Prostate Cancer Prostatic Dis | 2023 |
| 37865591 | Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS â¿¥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score. | Eur Urol Focus | 2023 |
| 37755520 | The impact of a second MRI and re-biopsy in patients with initial negative mpMRI-targeted and systematic biopsy for PIRADS⿿⿥⿿3 lesions. | World J Urol | 2023 |
| 37748951 | Re: Jakob Klemm, Michael Rink, Markus von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.005. | Eur Urol Focus | 2023 |
| 37739916 | The Highest Grade Group Does Not Drive the Risk of Recurrence when Systematic and Multiparametric Magnetic Resonance Imaging (MRI)-targeted Biopsies are Discordant: Preliminary Findings Using Radical Prostatectomy Pathology as a Surrogate for MRI-targeted Biopsy Grade. | Eur Urol Focus | 2023 |
| 37545342 | Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate-specific antigen concentrations. | Prostate | 2023 |
| 37646515 | Urinary continence in high-risk prostate cancer after robot-assisted radical prostatectomy. | Curr Opin Urol | 2023 |
| 37777767 | Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer. | BMC Urol | 2023 |
| 37603006 | Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions. | Curr Opin Urol | 2023 |
| 37671725 | Early Detection of Prostate Cancer: AUA/SUO Guideline. Letter. | J Urol | 2023 |
| 37530704 | The role of nuclear medicine tracers for prostate cancer surgery: from preoperative to intraoperative setting. | Curr Opin Urol | 2023 |
| 37326656 | Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer. | World J Urol | 2023 |
| 37019997 | Magnetic resonance imaging (MRI) for local staging before salvage radical prostatectomy: a meta-analysis. | World J Urol | 2023 |
| 37117107 | Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review. | Eur Urol | 2023 |
| 37052482 | Reply by Authors. | J Urol | 2023 |
| 37052480 | Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study That Challenges the Dogma. | J Urol | 2023 |
| 37183078 | Re: Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography-based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 Guideline. | Eur Urol Oncol | 2023 |
| 37182119 | Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer. | Eur Urol Open Sci | 2023 |
| 37046687 | PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment. | Cancers (Basel) | 2023 |
| 37449312 | Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter. | J Urol | 2023 |
| 36943477 | Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion? | World J Urol | 2023 |
| 37141845 | Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy. | Eur J Radiol | 2023 |
| 37005213 | Is Active Surveillance an Option for the Management of Men with Low-grade Prostate Cancer and a Positive Family History? Results from a Large, Single-institution Series. | Eur Urol Oncol | 2023 |
| 37100648 | Moving the Needle: Antibiotic Prophylaxis Is No Longer Required in the Era of Transperineal Prostate Biopsy. | Eur Urol | 2023 |
| 37365054 | Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion. | Clin Genitourin Cancer | 2023 |
| 37166270 | Salvage lymphadenectomy after primary therapy with curative intent for prostate cancer. | Curr Opin Urol | 2023 |
| 36999843 | Experience in Multiparametric magnetic resonance prior to targeted prostate biopsy: the tip of the iceberg for cancer detection? | Minerva Urol Nephrol | 2023 |
| 37198026 | Impact of the time elapsed between prostate biopsy and surgery on the accuracy of nomograms predicting lymph node invasion in patients with clinically localized prostate cancer. | Urol Oncol | 2023 |
| 37263905 | Re: Caroline M. Moore, Lauren E. King, John Withington, et al. Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting. Eur Urol Oncol. Eur Urol Oncol. 2023;6:160-82. | Eur Urol Oncol | 2023 |
| 37261474 | European guidelines update on PSMA PET/CT for prostate cancer staging-snap back to reality. | Eur J Nucl Med Mol Imaging | 2023 |
| 36697321 | Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer-Evidence from Recent Prospective Reports. | Eur Urol Focus | 2023 |
| 36813620 | Re: Philipp Mandel, Benedikt Hoeh, Mike Wenzel, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.08.007. | Eur Urol Focus | 2023 |
| 36746729 | Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study. | Eur Urol Focus | 2023 |
| 36609130 | The Changing Face of cN0M0 Prostate Cancer Being Found With pN+ After Surgery in the Contemporary Era: Results of an International European Survey on Disease Management. | Clin Genitourin Cancer | 2023 |
| 36804735 | Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review. | Eur Urol Oncol | 2023 |
| 36774224 | Re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80. | Eur Urol | 2023 |
| 36774225 | Re: Kerrington Powell, Michael C. Burns, Vinay Prasad. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint. Eur Urol. 2023;83:101-2. | Eur Urol | 2023 |
| 36428165 | Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis. | Urol Oncol | 2023 |
| 36707322 | Re: Bo Dai, Sheng Zhang, Fan-Ning Wan, et al. Combination of Androgen Deprivation Therapy with Radical Local Therapy Versus Androgen Deprivation Therapy Alone for Newly Diagnosed Oligometastatic Prostate Cancer : A Phase 2 Randomized Controlled Trial. Eur Urol Oncol 2022;5:519-25. | Eur Urol Oncol | 2023 |
| 36534151 | Risk and predictors of adverse pathology after radical prostatectomy in patients diagnosed with IUSP 1-2 prostate cancer at MRI-targeted biopsy: a multicenter analysis. | World J Urol | 2023 |